Welcome to our dedicated page for Rapt Therapeutics SEC filings (Ticker: RAPT), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
Decoding a biotech filing packed with trial protocols, CCR4 pathway charts, and milestone clauses can drain hours. RAPT Therapeutics SEC filings explained simply turns that struggle into clarity. Whether you’re scanning how Phase 2 data shifts cash burn or checking royalty obligations, our platform surfaces what matters in seconds.
Stock Titan’s AI reads every RAPT Therapeutics annual report 10-K simplified, each RAPT Therapeutics quarterly earnings report 10-Q filing, and the swift RAPT Therapeutics 8-K material events explained, then highlights clinical results, liquidity updates, and risk factors in plain language. Need to follow executives? Get RAPT Therapeutics Form 4 insider transactions real-time alerts that detail every RAPT Therapeutics executive stock transactions Form 4. The same dashboard links you to the RAPT Therapeutics proxy statement executive compensation so you can see how option grants align with drug-development milestones.
Investors use these insights to:
- Gauge safety signals before capital raises with our RAPT Therapeutics earnings report filing analysis
- Track tranche payments tied to trial enrollment via automated 8-K summaries
- Spot trends in RAPT Therapeutics insider trading Form 4 transactions ahead of data readouts
RAPT Therapeutics director Scott Braunstein received a stock option grant on June 21, 2025, as reported in this Form 4 filing. The derivative securities transaction details include:
- Grant of 25,000 stock options to purchase common stock
- Exercise price set at $7.43 per share
- Options expire on June 21, 2035
- Vesting schedule: Equal annual installments over three years from grant date
This equity compensation grant appears to be part of the company's standard director compensation program. The options were granted with direct ownership form, and the filing was submitted by attorney-in-fact Rodney Young on June 24, 2025. This transaction represents a new position for the director, as no prior holdings were reported in the filing.
RAPT Therapeutics has filed a Form 3 (Initial Statement of Beneficial Ownership) for newly appointed Director Scott Braunstein, effective June 21, 2025. The filing discloses that Mr. Braunstein currently holds no beneficial ownership of any securities in the company, either direct or indirect.
Key details from the filing:
- Position: Director (non-employee)
- Filing Status: Individual filing
- Business Address: 561 Eccles Avenue, South San Francisco, CA 94080
- No ownership of non-derivative securities reported
- No ownership of derivative securities (options, warrants, etc.) reported
The Form 3 was signed by Rodney Young as Attorney-in-Fact on June 24, 2025, fulfilling the SEC requirement for new insiders to report their initial securities ownership within 10 days of becoming an officer, director, or 10% owner.
RAPT Therapeutics Chief Medical Officer William Ho received a new stock option grant on June 20, 2025. The derivative securities transaction details include:
- Grant of 75,000 employee stock options
- Exercise price set at $7.43 per share
- Options expire on June 19, 2035
- Vesting schedule: 1/48th of shares vest monthly from June 20, 2025
This Form 4 filing, signed by attorney-in-fact Rodney Young, represents a standard equity compensation grant to a key executive officer. The ten-year option grant suggests a long-term retention strategy for the Chief Medical Officer position. The monthly vesting schedule over four years aligns with typical industry practices for executive compensation.
RAPT Therapeutics President and CEO Brian Russell Wong received a significant stock option grant on June 20, 2025. The derivative securities transaction involved:
- Grant of 637,500 stock options to purchase common stock
- Exercise price set at $7.43 per share
- Options expire on June 19, 2035
- Vesting schedule: 1/48th of shares vest monthly starting June 20, 2025
This Form 4 filing discloses the equity-based compensation grant to Wong, who serves as both Director and CEO. The substantial option grant, which represents direct ownership, appears to be part of the company's executive compensation strategy to align management interests with shareholders over a long-term ten-year period.
RAPT Therapeutics Chief Financial Officer Rodney Young received a significant stock option grant on June 20, 2025. The derivative securities transaction involves:
- Grant of 118,750 stock options to purchase common stock
- Exercise price set at $7.43 per share
- Options expire on June 19, 2035
- Vesting schedule: 1/48th of shares vest monthly starting June 20, 2025
This Form 4 filing indicates a standard executive compensation arrangement through equity incentives. The 10-year option grant with monthly vesting over 4 years suggests a long-term retention strategy for the CFO. The direct ownership structure of these derivatives aligns with typical executive compensation practices.
RAPT Therapeutics Chief Scientific Officer Dirk G. Brockstedt received a new stock option grant on June 20, 2025. The derivative securities transaction details include:
- Grant of 100,000 stock options to purchase common stock
- Exercise price set at $7.43 per share
- Options expire on June 19, 2035
- Vesting schedule: 1/48th of shares vest monthly from June 20, 2025
This Form 4 filing represents a standard equity compensation grant to a senior executive, likely as part of the company's long-term incentive program. The 10-year option term and 4-year monthly vesting schedule are typical for executive compensation in the biotech industry, designed to promote long-term retention and align management interests with shareholders.
RAPT Therapeutics (Nasdaq: RAPT) filed an 8-K reporting governance changes effective June 21 2025.
The Board expanded from five to seven directors and appointed Scott Braunstein, M.D. and Ashley Dombkowski, Ph.D. as Class III directors, with terms running through the 2028 annual meeting. Dr. Braunstein joins the Audit Committee, while Dr. Dombkowski joins the Nominating & Corporate Governance Committee.
The filing also notes an amendment to the non-employee director compensation policy; new directors now receive a one-time option grant for 25,000 common shares. Both directors executed standard indemnification agreements, and the company states that no related-party transactions exist under Item 404(a).
FAQ
What is the current stock price of Rapt Therapeutics (RAPT)?
What is the market cap of Rapt Therapeutics (RAPT)?
What is the primary focus of RAPT Therapeutics, Inc.?
How does RAPT Therapeutics generate its drug candidates?
Which therapeutic areas does RAPT address?
What distinguishes RAPT’s approach to drug development?
Can you explain the significance of the CCR4 target in their pipeline?
What are some of the key drug candidates in RAPT's pipeline?
How does RAPT Therapeutics position itself within the competitive biopharmaceutical landscape?
What type of clinical trials does the company undertake?
